Market Closed -
Nasdaq
21:00:00 02/05/2024 BST
|
5-day change
|
1st Jan Change
|
1.6
USD
|
+3.23%
|
|
+28.00%
|
-23.81%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
340.5
|
1,425
|
639.1
|
91.02
|
103
|
81.94
|
-
|
-
|
Enterprise Value (EV)
1 |
212.2
|
1,231
|
406.9
|
-76.63
|
37.13
|
75.14
|
-14.67
|
37.86
|
P/E ratio
|
-7.84
x
|
-30.5
x
|
-9.58
x
|
-0.8
x
|
-0.93
x
|
-1.01
x
|
-1.15
x
|
-1.64
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
5.22
x
|
18.1
x
|
7.47
x
|
1.4
x
|
1.4
x
|
1.11
x
|
0.97
x
|
0.71
x
|
EV / Revenue
|
3.25
x
|
15.7
x
|
4.76
x
|
-1.18
x
|
0.51
x
|
1.02
x
|
-0.17
x
|
0.33
x
|
EV / EBITDA
|
-12
x
|
-33.8
x
|
-6.86
x
|
0.72
x
|
-0.38
x
|
-0.98
x
|
0.2
x
|
-0.5
x
|
EV / FCF
|
-
|
-26,826,314
x
|
-4,967,778
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
3.19
x
|
7.34
x
|
2.07
x
|
0.42
x
|
0.82
x
|
1.01
x
|
1.09
x
|
1.6
x
|
Nbr of stocks (in thousands)
|
31,234
|
38,933
|
44,784
|
45,971
|
49,031
|
51,210
|
-
|
-
|
Reference price
2 |
10.90
|
36.61
|
14.27
|
1.980
|
2.100
|
1.600
|
1.600
|
1.600
|
Announcement Date
|
25/03/20
|
25/02/21
|
24/02/22
|
23/02/23
|
28/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
65.21
|
78.65
|
85.49
|
65.05
|
73.48
|
74
|
84.82
|
115.3
|
EBITDA
1 |
-17.67
|
-36.39
|
-59.34
|
-107.1
|
-98.64
|
-76.96
|
-74.62
|
-75.6
|
EBIT
1 |
-22.42
|
-42.15
|
-65.35
|
-115.5
|
-109.9
|
-80.99
|
-75.46
|
-65.91
|
Operating Margin
|
-34.38%
|
-53.59%
|
-76.44%
|
-177.61%
|
-149.61%
|
-109.43%
|
-88.97%
|
-57.16%
|
Earnings before Tax (EBT)
1 |
-25.08
|
-41.22
|
-65.21
|
-113.3
|
-108.2
|
-77.51
|
-73.1
|
-62.93
|
Net income
1 |
-25.08
|
-41.28
|
-65.23
|
-113.3
|
-108.3
|
-77.53
|
-73.1
|
-62.93
|
Net margin
|
-38.47%
|
-52.49%
|
-76.29%
|
-174.2%
|
-147.38%
|
-104.77%
|
-86.18%
|
-54.58%
|
EPS
2 |
-1.390
|
-1.200
|
-1.490
|
-2.480
|
-2.250
|
-1.578
|
-1.388
|
-0.9750
|
Free Cash Flow
|
-
|
-45.9
|
-81.91
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-58.36%
|
-95.81%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
25/03/20
|
25/02/21
|
24/02/22
|
23/02/23
|
28/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
22.26
|
20.68
|
15.23
|
18.24
|
14.86
|
16.72
|
18.86
|
16.7
|
18.25
|
19.76
|
18.36
|
18.41
|
18.7
|
18.55
|
16.1
|
EBITDA
1 |
-16.19
|
-18.62
|
-26.53
|
-26.06
|
-25.38
|
-29.13
|
-27.04
|
-22.5
|
-22.47
|
-21.06
|
-20.1
|
-16.25
|
-15
|
-16.05
|
-
|
EBIT
1 |
-17.69
|
-20.22
|
-28.31
|
-27.88
|
-27.26
|
-32.08
|
-29.82
|
-25.35
|
-25.23
|
-23.97
|
-19.89
|
-19.7
|
-19.96
|
-20.29
|
-21
|
Operating Margin
|
-79.47%
|
-97.79%
|
-185.89%
|
-152.86%
|
-183.46%
|
-191.87%
|
-158.14%
|
-151.78%
|
-138.26%
|
-121.29%
|
-108.37%
|
-107%
|
-106.7%
|
-109.42%
|
-130.43%
|
Earnings before Tax (EBT)
1 |
-17.66
|
-20.2
|
-28.2
|
-27.53
|
-26.48
|
-31.06
|
-28.64
|
-23.92
|
-29.07
|
-26.58
|
-19.05
|
-18.94
|
-19.3
|
-19.67
|
-20.3
|
Net income
1 |
-17.67
|
-20.2
|
-28.21
|
-27.55
|
-26.49
|
-31.07
|
-28.66
|
-23.96
|
-29.1
|
-26.58
|
-19.05
|
-18.94
|
-19.32
|
-19.67
|
-20.3
|
Net margin
|
-79.38%
|
-97.66%
|
-185.26%
|
-151.02%
|
-178.3%
|
-185.79%
|
-151.96%
|
-143.45%
|
-159.47%
|
-134.5%
|
-103.79%
|
-102.87%
|
-103.28%
|
-106.07%
|
-126.09%
|
EPS
2 |
-0.4000
|
-0.4500
|
-0.6300
|
-0.6000
|
-0.5800
|
-0.6700
|
-0.6100
|
-0.5000
|
-0.6000
|
-0.5400
|
-0.4067
|
-0.3883
|
-0.3950
|
-0.3883
|
-0.3925
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
04/11/21
|
24/02/22
|
04/05/22
|
03/08/22
|
02/11/22
|
23/02/23
|
03/05/23
|
08/08/23
|
07/11/23
|
28/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
128
|
194
|
232
|
168
|
65.8
|
6.79
|
96.6
|
44.1
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-45.9
|
-81.9
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-27.4%
|
-25.8%
|
-42.9%
|
-62.3%
|
-80.7%
|
-70.5%
|
-49%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
3.410
|
4.990
|
6.910
|
4.670
|
2.560
|
1.580
|
1.470
|
1.000
|
Cash Flow per Share
|
-1.000
|
-1.240
|
-1.610
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
3.25
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
4.13%
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
25/03/20
|
25/02/21
|
24/02/22
|
23/02/23
|
28/02/24
|
-
|
-
|
-
|
Average target price
4.6
USD Spread / Average Target +187.50% Consensus |
1st Jan change
|
Capi.
|
---|
| -23.81% | 81.94M | | +26.28% | 48.09B | | +48.09% | 40.62B | | -3.99% | 40.43B | | -6.20% | 28.36B | | +6.36% | 24.89B | | -21.47% | 19.01B | | +27.58% | 12.09B | | -2.02% | 11.88B | | -2.75% | 11.8B |
Other Biotechnology & Medical Research
|